Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257428 | 0.87 | GSK3B (0.39) | GSK3BALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17257141 | 0.87 | SMN1; SMN2 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL17257243 | 0.84 | DRD4 (0.44) | GSK3BALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17256863 | 0.82 | NPC1 (0.43) | GSK3BSMN1; SMN2VNN1GRM5NPC1 | |
| SCHEMBL17256861 | 0.82 | NPC1 (0.43) | GSK3BSMN1; SMN2VNN1GRM5NPC1 | |
| SCHEMBL212674 | 0.81 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL17257288 | 0.79 | GSK3B (0.46) | GSK3BALDH1A1SMN1; SMN2VNN1GRM5 | |
| SCHEMBL17257022 | 0.76 | SMN1; SMN2 (0.56) | GSK3BALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17256811 | 0.75 | L3MBTL1 (0.45) | GSK3BALDH1A1SMN1; SMN2VNN1GRM5 | |
| SCHEMBL17256812 | 0.75 | L3MBTL1 (0.45) | GSK3BALDH1A1SMN1; SMN2VNN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| EP-3143055-B1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | PAM, PPOX, MB | GSK3B 1448/4885ALDH1A1 3041/4885CYP1A2 639/4885 |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | PAM, PPOX, MB | GSK3B 1448/4885ALDH1A1 3041/4885CYP1A2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.